15-4-3　ⓔ文献

  1. Thienpont LM, Van Uytfanghe K, et al: Harmonization of serum thyroid-stimulating hormone measurements paves the way for the adoption of a more uniform reference interval. Clin Chem, 2017; 63: 1248–1260.

  2. Favresse J, Burlacu MC, et al: Interferences with thyroid function immunoassays: clinical implications and detection algorithm. Endocr Rev, 2018; 39: 830–850.

  3. Takamatsu J, Sugawara M, et al: Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine–predominant Graves’ disease. Ann Intern Med, 1984; 100: 372–375.

  4. Roelfsema F, Veldhuis JD: Thyrotropin secretion patterns in health and disease. Endocr Rev, 2013; 34: 619–657.

  5. Peeters RP: Subclinical Hypothyroidism. N Engl J Med, 2017; 376: 2556–2565.

  6. Ito M, Miyauchi A, et al: Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid, 2017; 27: 484–490.

  7. Miyauchi A, Kudo T, et al: Prognostic impact of serum thyroglobulin doubling–time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid, 2011; 21: 707–716.

  8. Torres MR, Nobrega Neto SH, et al: Thyroglobulin in the washout fluid of lymph–node biopsy: what is its role in the follow–up of differentiated thyroid carcinoma? Thyroid, 2014; 24: 7–18.

  9. Nishihara E, Amino N, et al: Comparison of thyroglobulin and thyroid peroxidase antibodies measured by five different kits in autoimmune thyroid diseases. Endocr J, 2017; 64: 955–961.

  10. Nishihara E, Amino N, et al: Moderate frequency of anti–thyroglobulin antibodies in the early phase of subacute thyroiditis. Eur Thyroid J, 2019; 8: 268–272.

  11. Tozzoli R, Bagnasco M, et al: TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta–analysis. Autoimmun Rev, 2012; 12: 107–113.

  12. Kamijo K, Murayama H, et al: Similar clinical performance of a novel chimeric thyroid–stimulating hormone receptor bioassay and an automated thyroid–stimulating hormone receptor binding assay in Graves’ disease. Thyroid, 2011; 21: 1295–1299.

  13. 日本甲状腺学会：甲状腺ホルモン不応症診断基準．http://www.japanthyroid.jp/doctor/img/hormone03.pdf

  14. Wells SA, Jr, Asa SL, et al: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015; 25: 567–610.

  15. Haugen BR, Alexander EK, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26: 1–133.

  16. Nikiforova MN, Mercurio S, et al: Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer, 2018; 124: 1682–1690.

  17. Ota H, Amino N, et al: Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves’ disease. Clin Endocrinol (Oxf), 2007; 67: 41–45.

  18. Fukata S, Hishinuma A, et al: Diagnosis of iodide transport defect: do we need to measure the saliva/serum radioactive iodide ratio to diagnose iodide transport defect? Thyroid, 2010; 20: 1419–1421.